Acadia Pharmaceuticals won't continue studying its neurological disease drug pimavanserin in schizophrenia patients who don't respond well to antipsychotic therapy, announcing Monday afternoon ...
Fresh data suggest AbbVie could face competition from a much smaller biotech, Myovant Sciences, as both companies work to gain U.S. approval for their respective drugs as uterine fibroids treatments. ...
Biogen is putting greater emphasis on its ambitions in eye and immune system diseases, likely in response to investor concerns over the company's high-risk neuroscience pipeline and the recent setback ...
The deal with Hikma is an important step forward for the ambitions of Civica, which formed as a way to secure a supply of off-patent medicine at more predictable prices. Thirty health systems with 900 ...
The healthcare system generates approximately a zettabyte (a trillion gigabytes) of data each year, which includes both classic data from sources such as EHRs, diagnostics and genetics, as well as ...
Second quarter earnings kick into full gear this week as nearly a dozen pharmas and biotechs report. Broad challenges, such as the pronounced role drug pricing will play in the 2020 election cycle, ...
The Food and Drug Administration rejected an application from Biohaven Pharmaceuticals for approval of its ALS drug, citing ...
Four generics companies could face about $14.7 billion in potential penalties related to legal actions, including lawsuits alleging mis-marketing of opioid pills as well as accusations that the ...
John Pottage, the chief science and medical officer at the majority GlaxoSmithKline-owned ViiV Healthcare, will soon step down, handing off his duties to two current ViiV executives by October 1. ...
Rare disease company Ultragenyx Pharmaceutical is due to soon receive key mid-stage data from its two lead gene therapy programs that, if positive, could pave the way to pivotal trials and submissions ...
Working with Catalent gives Novartis another avenue for producing Zolgensma (onasemonogene abeparvovec) and the viruses used to deliver it. Currently, commercial supply of Zolgensma is produced at an ...
Wall Street analysts have crafted a short list of companies most likely to acquire Celgene's anti-inflammation drug Otezla, with top names including Gilead, Amgen and Johnson & Johnson. Gilead has its ...